Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19

NCT04674566 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19

Interventions

DRUG: COR-101
DRUG: Placebo

Sponsor

Corat Therapeutics Gmbh